转自：智通财经 【国际医学：拟募资不超10.08亿元 用于智慧康养项目等】智通财经12月3日电，国际医学(000516.SZ) 公告称，公司本次向特定对象发行股票拟募集资金总额不超过10.08亿元（含），扣除发行费用后，募 集资金拟投资于智慧康养项目、质子治疗中心二期项目以及补充流动资金。 ...

国际医学公告，公司2025年度拟向特定对象发行股票募集资金不超过10.08亿元，扣除发行费用后将用 于智慧康养项目、质子治疗中心二期项目及补充流动资金。 （文章来源：第一财经） ...

Core Viewpoint - International Medical has achieved significant recognition in the healthcare sector in Xi'an, with its hospitals ranking highly in customer satisfaction and service quality [2][3] Summary by Categories Company Achievements - Xi'an International Medical Center Hospital ranked second in the "2024 Annual Customer Satisfaction Survey" for the entire healthcare industry in Shaanxi and received the "Best Service Unit" award [2][3] - Xi'an International Medical Center Hospital was also ranked first in the "Top 10 Single Hospitals in the Northwest Region" for the 2024-2025 period, while Xi'an High-tech Hospital secured the second position in the same category [2][3] Industry Positioning - The company is positioned as a representative comprehensive medical service listed company in the secondary market, having established a full-spectrum health service platform that covers medical services, rehabilitation, and elderly care [2][3] - The company has built a comprehensive medical service network that is deeply rooted in Xi'an, based in Shaanxi, and radiating throughout the central and western regions of China [2][3]

Core Insights - The company is enhancing operational efficiency through clinical pathway management, reducing drug consumption ratio, and optimizing cost structure while continuously improving the quality of medical services [1] Financial Performance - As of Q3 2025, the company's management expense ratio is 10.99%, a decrease of 0.54 percentage points year-on-year and a decrease of 2.13 percentage points quarter-on-quarter [1] - The financial expense ratio stands at 3.43%, reflecting a year-on-year decrease of 0.07 percentage points and a quarter-on-quarter decrease of 0.25 percentage points, indicating initial success in cost control [1] Future Outlook - The company plans to continue its cost control efforts, with expectations for further optimization of financial costs as depreciation, amortization, and interest expenses decline [1]

Core Insights - The core focus of the national medical reform is to establish a "tiered diagnosis and treatment" system and implement a healthcare payment reform primarily based on DRG/DIP [1] Group 1: Industry Trends - The reform aims to guide medical institutions towards enhancing service quality and innovating service models, with tertiary hospitals being more competitive in complex case management, clinical pathway optimization, and medical resource utilization efficiency [1] - The company is actively adjusting its business structure to enhance service value and build competitive advantages through differentiated strategies [1] Group 2: Company Strategy - The company has developed multiple specialized departments, including neurology, cardiovascular, digestive, thoracic, oncology, hematology, and orthopedics, and is engaged in high-tech, complex medical projects that align with the DRG reform direction [1] - The company is expanding into various business segments such as aesthetic medicine, rehabilitation, maternal and child health, health management, traditional Chinese medicine, assisted reproduction, mental health, and special services [1] - The company is also opening specialized departments like elderly care facilities, Huibin departments, and proton therapy to meet market demand [1]

Core Viewpoint - The company emphasizes its commitment to modern corporate governance and transparency, ensuring the protection of shareholder rights and sustainable development [1]. Group 1: Corporate Governance - The company has established a governance structure centered around the shareholders' meeting, board of directors, and management team, adhering to relevant laws and regulations [1]. - The company operates under a "group management, branch operation" model, with its medical institutions implementing modern corporate systems and specialized management practices [1]. Group 2: Operational Efficiency - The company has a well-functioning corporate governance structure and internal control systems that enhance operational efficiency and improve business capabilities [1].

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司业绩考核标准是怎样的？收入和盈利都在 持续下滑，为什么没有看到费用降低呢？ 国际医学（000516.SZ）12月2日在投资者互动平台表示，公司旗下医疗机构在持续优化医疗服务质量的 同时，通过临床路径管理、降低药耗占比、优化成本结构等方式提高运营效率，实现提质增效。2025年 第三季度，公司管理费用率为10.99%，同比下降0.54个百分点，环比下降2.13个百分点；财务费用率为 3.43%，同比下降0.07个百分点，环比下降0.25个百分点，成本管控初见成效。未来公司将持续推进成 本管控，随着折旧摊销及利息费用下降，财务成本有望进一步优化。 ...

证券之星消息，国际医学(000516)12月01日在投资者关系平台上答复投资者关心的问题。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 投资者提问：请问贵公司是否为家族企业或者裙带企业？ 国际医学回复：您好，感谢您对公司的关注。国际医学作为一个已上市的公众公司，自创立以来，始终 致力于建立并不断完善现代化的企业治理结构，以确保公司的专业化、规范化和可持续发展。公司严格 遵循《公司法》《证券法》及上市公司治理准则等法律法规，建立了以股东会、董事会和经营管理层为 核心的治理架构，有效保障所有股东的合法权益，确保公司重大决策的科学性与透明度。公司采用"集 团化管理，分院区经营"的模式，旗下医疗机构建立了完善的现代化企业制度和专业的医疗技术、人力 资源、财务管理、专业培训等管理体系。公司具备健全且运行良好的法人治理结构，建立了健全的内部 控制制度，能够有效保证公司运行的效率、提高公司的经营能力。谢谢！ ...

Core Viewpoint - The company is addressing investor concerns regarding declining revenue and profits while maintaining operational efficiency through cost management strategies [1] Financial Performance - As of Q3 2025, the company's management expense ratio is 10.99%, showing a year-on-year decrease of 0.54 percentage points and a quarter-on-quarter decrease of 2.13 percentage points [1] - The financial expense ratio stands at 3.43%, with a year-on-year decrease of 0.07 percentage points and a quarter-on-quarter decrease of 0.25 percentage points [1] Cost Management Strategies - The company is focusing on optimizing medical service quality, clinical pathway management, reducing drug consumption, and optimizing cost structure to enhance operational efficiency [1] - Future efforts will continue to emphasize cost control, with expectations for further optimization of financial costs as depreciation and interest expenses decline [1]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]